Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-In-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Next Previous
X
Search
Trial Profile

A Phase 1, First-In-Human, Multiple Part, Single Ascending and Multiple Dose Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNT-517 (Primary) ; JNT-517 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Jnana Therapeutics

    • Most Recent Events

    • 24 Sep 2024 According to Otsuka Pharmaceutical media release, the company is currently engaging in discussions with U.S. and European regulatory authorities and plans to initiate a Phase 3 study in early 2025.
    • 04 Sep 2024 According to a Jnana therapeutics media release, Results from this study were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium.
    • 04 Sep 2024 Results presented in the Jnana therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top